| Popis: |
BackgroundThe limitations of the biomarker prostate-specific antigen (PSA) necessitate the pursuit of biomarkers capable of better identifying high-risk prostate cancer (PC) patients in order to improve their therapeutic management and outcome. Aggressive prostate tumors characteristically exhibit high rates of glycolysis and lipogenesis. Glycerol 3-phosphate phosphatase (G3PP), also known as phosphoglycolate phosphatase (PGP), is a recently identified mammalian enzyme, shown to play an important role in the regulation of glucose metabolism, lipogenesis, lipolysis and cellular nutrient excess detoxification. We hypothesized that G3PP is involved in cancer cell growth and assessed the association of its expression with PC patient prognosis. MethodsUsing immunohistochemical staining we assessed the epithelial expression of G3PP in two different radical prostatectomy cohorts with a total of 1797 patients, for whom information on biochemical recurrence (BCR), metastasis and mortality is available. Association between biomarker expression, biochemical recurrence (BCR), bone metastasis and prostate cancer specific survival was established using log-rank and multivariable Cox regression analyses.ResultsHigh expression of G3PP prostate cancer epithelial cells is associated with an increased risk of BCR, bone metastasis and prostate cancer specific mortality. Multivariate analysis revealed high G3PP expression in tumors as an independent predictor of BCR and bone metastasis development. ConclusionsHigh G3PP expression in tumor from patients eligible for prostatectomies is a new and independent prognostic biomarker of poor prognosis and aggressive prostate cancer specifically for recurrence, bone metastasis and mortality. |
